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Aims: The aim of this study is to evaluate effectiveness and safety of basal supported oral therapy (BOT) using
insulin glargine in insulin-naive Japanese patients, with and without microvascular complications.
Methods: This sub-group analysis of observational, non-interventional ALOHA study, assessed changes in
glycemic parameters and glargine dose, at 24 weeks or at glargine discontinuation. Count of hypoglycemic
episodes was based on physicians' documentation of patient reports. Patients were stratiﬁed according to
presence/absence of microvascular complications, at baseline. Relationships between baseline patient
characteristics and achievement of HbA1c b7% were examined by multivariate regression analysis.
Results: A total of 3631 patients, included during 2007–2009, were stratiﬁed in sub-groups: no complications (n =
1889), retinopathy (n = 318), neuropathy (n = 297), nephropathy (n = 356), retinopathy + neuropathy (n =
174), retinopathy + nephropathy (n = 154), neuropathy + nephropathy (n = 142), and retinopathy + neur-
opathy + nephropathy (n = 301). Changes in HbA1c, fasting and postprandial plasma glucose, and glargine daily
dose were similar among patients with and without complications. Response-rate for achieving HbA1c b7.0% was
highest in patients without complications (19.1%). In multivariate analysis, patients without complications showed
signiﬁcantlyhigheroddsof attainingHbA1cb7%, independentof diabetesdurationandbaselineHbA1c levels. Patients
with retinopathy + nephropathy had the lowest response-rate (8.8%) and highest hypoglycemic-rate (3.2%).
Conclusion: Japanese insulin-naive patients without complications, on BOT with glargine, show higher chances of
attaining HbA1c b7.0% than those with complications.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Background
Diabetes poses a signiﬁcant economic burden in Japan; an estimated
7.1 million adults in Japan had diabetes in 2010, which corresponds to
5.0% prevalence after adjusting to the world adult population (Shaw,
Sicree, & Zimmet, 2010). Chronic hyperglycemia leads to microvascular
complications such as nephropathy, retinopathy, and neuropathy;isory board fees, lecture fees,
Sanoﬁ K. K. Takashi Kadowaki
ip grants fees from Sanoﬁ K.K.
-2,Nishi-Shinjuku, Shinjuku-ku,
6301 3022.
wara),
aito@sanoﬁ.com (Y. Naito).
Inc. This is an open access article ufurther decreasing quality of life, reducing life expectancy, and
increasing the economic burden (Gerich, 2005; Girach, Manner, &
Porta, 2006). In Japanese patientswith type 2 diabetesmellitus (T2DM),
medical costs of patients with nephropathy are 2.1-fold higher,
retinopathy are 2.6-fold higher, and neuropathy are 3.3-fold higher
than those without complications (Neville et al., 2009).
Earlier observational studies show that increased glycosylated
hemoglobin (HbA1c) is associated with increase in risk of microvascular
complications; and intensive glycemic control (as reﬂected by HbA1c)
curbs the onset of microvascular complications of diabetes, slows their
progression, and improvesqualityof life (Holman, Paul, Bethel,Matthews,
& Neil, 2008; Sabanayagam et al., 2009; Selvin et al., 2011; Stratton et al.,
2000; UK Prospective Diabetes Study (UKPDS) Group, 1998). However,
randomized clinical trials showthat beneﬁt:risk ratio of intensive glucose
lowering treatment in preventing microvascular complications is
uncertain (Boussageon et al., 2011; Duckworth et al., 2009).nder the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
128 M. Odawara et al. / Journal of Diabetes and Its Complications 29 (2015) 127–133Although the international guidelines recommend intensive glycemic
control by early initiation and intensiﬁcation of antidiabetic therapy with
oral antidiabetic drugs (OADs) and/or insulin, along with lifestyle
modiﬁcation (Nathan et al., 2009; Rodbard et al., 2009), an earlier
observational study in Asian patients highlights that in the real-world
insulin initiation is delayedby approximately 9 years (Tsai et al., 2011). This
can be attributed to physicians' and patients' reluctance to initiate insulin
therapy (Marrero, 2007; Peyrot et al., 2005). TheDiabetes Attitudes,Wishes
andNeeds(DAWN)Japanstudyalsoreportspracticalburdensasphysicians'
barriers to insulin initiation (Ishii, Iwamoto, & Tajima, 2012).
An earlier study in Japanese patients shows that 83.4% of patients
have microvascular complications at the time of initiating insulin
treatment (Freemantle et al., 2012; Kawamori et al., 2011). Studies in
Western population postulate that in patients with existing microvas-
cular complications and inadequate glycemic control, it is difﬁcult to
achieve strict glycemic control due to the risk of worsening the
complications or cardiovascular events (Calles-Escandon et al., 2010;
Patel et al., 2008; The Diabetes Control & Complications Trial Research
Group, 1998). In a clinical trial setting, an earlier study in Japanese
patients with T2DM, shows that intensive glycemic control by multiple
insulin therapy delays onset and progression of diabetic complications
(Ohkubo et al., 1995; Shichiri, Kishikawa, Ohkubo, & Wake, 2000). To
substantiate the growing evidence in support of early insulin initiation
before onset of microvascular complications to increase the chances of
achieving glycemic targets, we conducted a sub-analysis of the Add-on
Lantus® to Oral Hypoglycemic Agents (ALOHA) study (Ohtani & Ito,
2011). We evaluated effectiveness and safety of basal supported oral
therapy (BOT) using insulin glargine in insulin-naive Japanese T2DM
patients with and without microvascular complications.
2. Methods
2.1. Study design
ALOHA was an observational, non-interventional, post-marketing
surveillance study that recruited 5223 patients having inadequately
controlled T2DM, from 987 centers across Japan, between 2007 and
2009. The detailed design and methodology of the ALOHA study are
published in earlier articles (Kadowaki, Ohtani, & Odawara, 2013;
Odawara, Ohtani, & Kadowaki, 2012; Ohtani & Ito, 2011). This was a sub-
analysis of the ALOHA cohort, in which we selected data of insulin-naive
inadequately controlled T2DMpatients, whowere given BOT using insulin
glargine, and were followed for 24 weeks to determine association of
presence/absence of diabetic microvascular complications with the
effectiveness and safety of BOT using insulin glargine.
This study was endorsed by the Health Authority in Japan and was
conducted in accordance with the Good Post-marketing Study
Practice (GPSP) (Kumano, 2012), and Good Vigilance Practice (GVP)
(Good Pharmacovigilance Practices, 2014) in Japan.
2.2. Patients
The study included insulin-naive patients who satisﬁed the
following criteria within 4 weeks of screening period before initiation
of insulin glargine: (1) received treatment with OADs for ≥12 weeks,
(2) had HbA1c (National Glycohemoglobin Standardization Program
[NGSP]1) values≥7.9 and b12.5%, and (3) had bodymass index (BMI)
b30 kg/m2. Insulin-naive patients with non-diabetic renal disorders
were excluded.1 The NGSP values were selected based on the Japan Diabetic Society (JDS) values
(≥7.5 and b12.0%, respectively). HbA1c data were collected as JDS values and then
converted to NGSP values by the following conversion formula: HbA1c
(NGSP) = 1.02 × HbA1c (JDS) + 0.25% with rounding off to the ﬁrst decimal place
(The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes
Mellitus et al., 2010).2.3. Treatment
Initiation of insulin treatment and adjusting insulin doses were
determined by attending physicians. Concomitant OADs were also
selected by the physicians, as part of routine clinical care.
Patients who required additional insulin, for example, bolus insulin,
were terminated to follow-up due to no longer fulﬁlling the inclusion
criteria,which includedpatients treatedwithBOTusing insulin glargine.
2.4. Data collection
All eligible patients' data were collected via paper-based case
report forms. Data collected included background characteristics
(gender, age, weight, duration of diabetes, disease history, complica-
tions, prior OADs, etc.), treatment details, and adverse events (AEs).
2.5. Study assessment
Safety and effectiveness data were collected over 24 weeks.
Effectiveness parameters included HbA1c, fasting plasma glucose
(FPG), postprandial plasma glucose (PPG), and weight. Safety was
determined by documenting all AEs including hypoglycemia. In case
of serious AEs, we evaluated seriousness, intervention, outcome, and
causal relationship to insulin glargine.
Hypoglycemic episodes were counted by physicians' documenta-
tion (any hypoglycemic episodes and any symptoms derived from
hypoglycemia), based on patients' reports. Hypoglycemia was deﬁned
as hypoglycemia-related symptoms as the adverse drug reaction or
hypoglycemic episodes documented by physicians as the adverse
drug reaction. Severe hypoglycemia included hypoglycemic episodes
satisfying any of the following serious AEs criteria; (1) resulted in
death, (2) life-threatening, (3) required or prolonged inpatient
hospitalization, (4) persistently or signiﬁcantly disabling/incapacitat-
ing, (5) a congenital anomaly, and/or (6) medically important.
Westratiﬁed total patients into twogroupsdependingon thepresence
of diabetic microvascular complications: patients without complications
andpatientswith complications. Patientswith complicationswere further
divided into sub-groups as follows: (1) retinopathy only, (2) neuropathy
only, (3) nephropathy only, (4) retinopathy + neuropathy, (5) retino-
pathy + nephropathy, (6) neuropathy + nephropathy, and (7)
retinopathy + neuropathy + nephropathy.
2.6. Statistical analyses
The baseline characteristic difference in the mean among diabetic
microvascular complications groups was analyzed using one-way
analysis of variance (ANOVA), and chi-square test was used for
categorical variables. Changes in insulin glargine dose, HbA1c, FPG,
PPG, and weight between baseline and endpoint were examined by
paired t-test, according to diabetic microvascular complications
groups. Symptomatic and severe hypoglycemia were examined by
Fisher exact test. Multivariate logistic regression model was used to
calculate odds ratios and 95% conﬁdence intervals of diabetic
microvascular complications adjusted for other factors predicting
response to HbA1c b7.0% at endpoint. All statistical tests were two-
sided at α = 0.05. All statistical calculations were performed using
IBM SPSS Statistics, version 21 (SPSS Inc., Chicago, IL), except Fisher
exact test was executed by R version 2.15.2.
3. Results
3.1. Patient disposition and baseline characteristics
Of 5223 patients enrolled in the study, 5181 patients completed case
report forms.Of these, 4219patientswere included in the safetyanalysis
set (Supplementary ﬁle: Fig. 1). Of 3732 insulin-naive patients, we
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129M. Odawara et al. / Journal of Diabetes and Its Complications 29 (2015) 127–133excluded 101 patients with non-diabetic renal disorders, and analyzed
3631 insulin-naive patients. The analyzed patients were divided as
patients without microvascular complications (52.0%, n = 1889) and
patients with microvascular complications (48.0%, n = 1742). The
latter group was further divided into seven sub-groups as per the
various combinations of diabetic microvascular complications.
Baseline characteristics of total and sub-grouppatients arepresented
in Table 1. A total of 59.8% of patients weremale, withmean age 62.5 ±
12.0 years, and mean body mass index 23.7 ± 3.3 kg/m2. Majority of
patients (81.2%) had duration of T2DM ≥5 years, with mean HbA1c
9.54% ± 1.19%. Therewere 13.2% of patientswith estimated glomerular
ﬁltration rate (eGFR) levels b60 mL/min/1.73 m2, indicating poor renal
function. There were 9.6% of patients without complications with eGFR
b60 mL/min/1.73 m2. Statistical analysis was carried out to ﬁnd the
difference betweenmeasured variables of different groups. The result of
ANOVA showed that the difference in mean weight, BMI and HbA1c
among the groups were statistically signiﬁcant.
Before the study, 61.3% of patients received b3 OADs. The most
common OADs administered before the trial were sulfonylureas (n =
3587, 85.0%), biguanides (n = 1991, 47.2%) and alpha glucosidase
inhibitors (n = 1971, 46.7%) and during the trial were sulfonylureas
(n = 3558, 84.3%), biguanides (n = 1990, 47.2%) and alpha-glucosidase
inhibitors (n = 2030, 48.1%). In 87% (n = 3171) patients there was no
change in OADs before and during the study. (Table 2) Further details on
the type of OADs have been published earlier (Ohtani & Ito, 2011).
A total of 3182 (87.6%) patients completed the study, while 449
(12.4%) patients discontinued in b24 weeks. Themean starting dose,
endpoint dose and change of insulin dose in patients without
complications were 6.1, 9.5 and +3.4 U/day, respectively. Among
the sub-groups, the highest increase in the insulin dosewas observed
in the nephropathy alone (starting: 5.8 U/day, endpoint: 9.9 U/day,
change: +4.1 U/day) and retinopathy + nephropathy groups (starting:
5.6 U/day, endpoint: 9.7 U/day, change: +4.1 U/day), followed by
retinopathy + neuropathy + nephropathy group (starting: 5.5 U/day,
endpoint: 9.5 U/day, change: +4.0 U/day) (Table 2).
Table 3 presents data on change in HbA1c, FPG, PPG, and responder
rate among total and sub-group patients based on diabetic microvascular
complications. Among patients, without complications, the HbA1c
decreased by 1.47%, along with decrease in FPG (62.3 mg/mL) and PPG
(67.3 mg/mL). Among patients with complications, patients with
neuropathy + nephropathy showed highest decrease in HbA1c (1.59%),
followed by patients with neuropathy (1.52%). Patients with neuro-
pathy + nephropathy showed highest decrease in FPG (86.5 mg/mL),
followed by patientswith nephropathy (71.1 mg/mL). In case of decrease
in PPG, patients with neuropathy + nephropathy showed highest
decrease in PPG (84.3 mg/mL), followed by patients with retino-
pathy + nephropathy (80.1 mg/mL).
Among all sub-groups, there was a statistically signiﬁcant
difference in responder rates of HbA1c b7.0% at endpoint. Response
rate of achieving HbA1c b7.0% was the highest in patients without any
diabetic microvascular complications (19.1%). Patients with retino-
pathy + nephropathy had the lowest response rate (8.8%).
Theweight change inpatientswithout complicationsduring the study
period was 0.8 kg. Incidence of documented symptomatic hypoglycemia
by diabetic microvascular complications was marginally statistically
signiﬁcant across the patient sub-groups. Patients with retinopathy + -
nephropathy had the highest hypoglycemic rate (3.2%), whereas patients
with neuropathy + nephropathy had no hypoglycemic event. Among
patients without complications, 1.0 and 0.1% of patients had hypoglyce-
mia and severe hypoglycemia, respectively (Table 4).
3.2. Association between patient characteristics and achieving HbA1c
b7% in insulin-naive patients: multivariate analysis
Table 5 shows the relationships between baseline patient
characteristics and likelihood of reaching HbA1c b7%, as tested by
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130 M. Odawara et al. / Journal of Diabetes and Its Complications 29 (2015) 127–133multivariate logistic regression analysis in total 3239 patients after
excluding patients with missing values (n = 392). Higher baseline
HbA1c (OR 0.69, 95% CI: 0.63, 0.76), and presence of diabetic
retinopathy (OR 0.60, 95% CI: 0.41, 0.88), neuropathy (OR 0.67, 95%
CI: 0.46, 0.99), retinopathy + nephropathy (OR 0.44, 95% CI: 0.24,
0.81), retinopathy + neuropathy + nephropathy (OR 0.65, 95% CI:
0.44, 0.96) decreased the odds of achieving target HbA1c. Findings of
this analysis showed that duration of diabetes b1 year (OR 3.05, 95%
CI: 1.48, 6.31) and patients with older age (OR 1.02, 95% CI: 1.01, 1.03)
increased chances of achieving HbA1c b7%. Thus, patients without
complications showed signiﬁcantly higher odds of attaining HbA1c
b7% than patients with complications, independently of duration of
diabetes and baseline HbA1c levels.
4. Discussion
This sub-analysis of the observational, non-interventional, 24-week
post-marketing surveillanceALOHA study in Japanprovides, for the ﬁrst
time, detailed real-life information on effectiveness and safety of BOT
using insulin glargine in insulin-naive T2DM patients according to
presence/absence of diabetic microvascular complications.
T2DM is a progressive disease characterized by gradual loss of
insulin secretion, and the risk of developing microvascular complica-
tions increases with diabetes duration and the severity of hypergly-
cemia (Fowler, 2008). Diabetic retinopathy is known to cause
blindness among adults aged 20–74 years. In diabetic neuropathy,
asymptomatic distal symmetric polyneuropathy might pose risk for
insensate injury to feet, while autonomic neuropathy might lead to
morbidity and even mortality. Diabetic nephropathy is also known to
be the leading cause of end stage renal disease (American Diabetes
Association, 2013). Considering various modiﬁable risk factors of
microvascular complications, such as hyperglycemia, duration of
diabetes, hypertension, metabolic syndrome, etc. (Abdul-Ghani et al.,
2006; Paisey et al., 1984; Ramachandran et al., 1999), and associations
among the complications (Girach et al., 2006), it is crucial to prevent
microvascular disease, to reduce the associated morbidity and
mortality. Increasing awareness and patient/physician education
regarding early diagnosis/screening for T2DM and early insulin
initiation might help in controlling microvascular complications and
related health and economic burden (Marrero, 2007; Peyrot et al.,
2005; Spijkerman et al., 2003).
An earlier study in Japanese patients shows that 83.4% of T2DM
patients have microvascular complications at the time of initiating
insulin treatment (Freemantle et al., 2012; Kawamori et al., 2011). In
the present study also, as many as 48% of the insulin-naive patients
had various combinations of microvascular complications, including
retinopathy, neuropathy, and nephropathy. Early initiation of basal
insulin in inadequately controlled T2DM patients demonstrates
improvement in glycemic control (Blickle et al., 2009; Nathan et al.,
2009), which in turn decreases risk of microvascular complications
(UK Prospective Diabetes Study (UKPDS) Group, 1998; Holman et al.,
2008; Ohkubo et al., 1995; Shichiri et al., 2000). Insulin glargine is
convenient, efﬁcacious and safe in the treatment of T2DM (Barnett,
2006). An earlier clinical trial in Japanese T2DM patients, demon-
strates that BOT with insulin glargine decreases HbA1c levels during
28-week study period, suggesting suppression of progression of
complications (Kawamori, Iwamoto, Kadowaki, & Iwasaki, 2003). In
another study in Japanese T2DM insulin-naive patients, BOT using
insulin glargine signiﬁcantly improved HbA1c levels, without causing
serious hypoglycemia (Suzuki et al., 2012). In the present study also,
initiation of insulin glargine in BOT showed reductions in HbA1c, FPG
and PPG, along with low rate of hypoglycemia. The present study also
demonstrated that more patients without microvascular complica-
tions achieve HbA1c b7% as compared to patients with complications.
In the present study, multivariate logistic regression analysis
revealed that as compared to the patients without any diabetic
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131M. Odawara et al. / Journal of Diabetes and Its Complications 29 (2015) 127–133microvascular complications, patients with complications (especially
retinopathy, alone or in combination with neuropathy or nephropa-
thy) showed signiﬁcantly lower odds of attaining glycemic control of
HbA1c b7%. The statistical model of multivariate regression analysis,
eliminated the effect of confounding factors, showing that the diabetic
microvascular complications were risk factors of attaining the good
glycemic control measured by HbA1c (b7%), independent of duration
of diabetes and baseline HbA1c levels. These results are in line with
the earlier observational registry, International Diabetes Management
Practice Study (IDMPS), which showed that in Asian T2DM patients,
lack of microvascular complications is predictor of HbA1c b7% (OR
0.82, 95% CI 0.693, 0.979) (Chan et al., 2009).
The beneﬁts of achieving adequate glycemic control with respect
to delaying onset and progression of diabetic microvascular compli-
cations, are counter-balanced with the relative risk of severe
hypoglycemia by 30% (Hemmingsen et al., 2011; Ismail-Beigi et al.,
2010). In Action in Diabetes and Vascular disease: PreterAx and
DiamicroN-MR Controlled Evaluation (ADVANCE) study, severe
hypoglycemia is associated with major microvascular events (hazards
ratio, 1.81; 95% CI 1.19, 2.74) (Zoungas et al., 2010). Diabetic
complications such as peripheral neuropathy, renal insufﬁciency,
and coronary artery disease are independent risk factors for ﬁrst and
multiple events of severe hypoglycemia (Davis et al., 2010; Lin et al.,
2010). In line with the earlier evidence, in the current study also,
hypoglycemia was associated with presence of diabetic complication
(s) (relative risk 1.36, 95% CI: 0.66, 2.83) (Odawara, Kadowaki, &
Naito, 2014). In the present study, though there was some difference
in incidence of hypoglycemia among diabetic microvascular compli-
cations, the difference and the absolute risk itself were small.
The present sub-analysis of the observational ALOHA study
provides information on effectiveness and safety of BOT using insulin
glargine as per the presence/absence of microvascular complications,
in real-life clinical practice in insulin-naive T2DM patients in Japan
having inadequate glycemic control. The stratiﬁcation on the basis of
type of complications lays the foundation for future exploratory
research to devise newer strategies for the attainment of glycemic
targets in patients with speciﬁc complications.
However, this population might not represent general T2DM
patient population who initiate insulin glargine. In addition, this sub-
analysis does not provide information on the worsening of the
microvascular complications from baseline to the end of the study,
after initiating BOT using insulin glargine. Unlike a treat-to-target
trial, the present observational study has no interventional target of
glycemic control. In this study, we gathered data from the clinical
records as reported by physicians, without any other validation.
Hence, because of the observational nature of the study, it is likely that
prevalence of diabetic microvascular complications is underestimated
or misclassiﬁed, due to the lack of precise deﬁnitions of the
complications. The changes in HbA1c in the various groups with and
without complications though statistically signiﬁcant, need to be
tested in various clinical settings in order to ascertain that they are
clinically meaningful.
In conclusion, in Japanese insulin-naive patients with T2DM
treated with BOT using insulin glargine, patients without any
complications show higher chances of reaching glycemic control
than those with complications, independent of duration of diabetes
and baseline HbA1c levels. Increasing awareness and patient/
physician education regarding early diagnosis of T2DM and early
insulin initiation might help in controlling microvascular complica-
tions and related health and economic burden.
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Table 5
Association of patient characteristics with achievement of HbA1c b 7% in insulin-naive
T2DM patients (n = 3239).
Patient
characteristics
Categories OR 95% CI P value
Lower Upper
Sex Men 1.18 0.97 1.44 0.098
Women Reference
Age 1 year increment 1.02 1.01 1.03 b0.001
Baseline HbA1c 1% increment 0.69 0.63 0.76 b0.001
Duration of diabetes b1 year 3.05 1.48 6.31 0.003
≥1 year, b5 years 1.25 0.93 1.69 0.135
≥5 years Reference
Unknown 1.67 1.16 2.41 0.006
Diabetic
microvascular
complications
None Reference
Retino 0.60 0.41 0.88 0.008
Neuro 0.67 0.46 0.99 0.044
Nephro 0.79 0.56 1.10 0.158
Retino + neuro 0.61 0.37 1.01 0.056
Retino + nephro 0.44 0.24 0.81 0.008
Neuro + nephro 0.64 0.38 1.10 0.105
Retino + neuro + nephro 0.65 0.44 0.96 0.029
Abbreviations: CI, conﬁdence interval; HbA1c, glycosylated hemoglobin; Nephro,
nephropathy; Neuro, neuropathy; OR, odds ratio; Retino, retinopathy.
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